Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
about
Latency: the hidden HIV-1 challenge.Redefining the viral reservoirs that prevent HIV-1 eradicationRecent developments in human immunodeficiency virus-1 latency researchAn "escape clock" for estimating the turnover of SIV DNA in resting CD4⁺ T cellsHIV reservoir size and persistence are driven by T cell survival and homeostatic proliferationHIV pathogenesis: dynamics and genetics of viral populations and infected cells.Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitroThe latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance.Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAARTReappearance of an 11-year-old sequence in an HIV-1 infected patient during treatment interruption.Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapyEvidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages.Impact of latently infected cells on strain archiving within HIV hosts.Reduced evolutionary rates in HIV-1 reveal extensive latency periods among replicating lineagesThe HBV drug entecavir - effects on HIV-1 replication and resistanceNeutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartmentsLatency in human immunodeficiency virus type 1 infection: no easy answers.Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapiesHIV-1 seronegativity in a child with proved perinatal HIV infection on HAARTThe next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules.Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutationsHuman immunodeficiency virus (HIV) latency: the major hurdle in HIV eradicationDynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age.Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.Experimental approaches to the study of HIV-1 latency.Regulation of HIV-1 latency by T-cell activation.Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loadsThe antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutationImmunology of pediatric HIV infectionAsymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips.Increased mutations in Env and Pol suggest greater HIV-1 replication in sputum-derived viruses compared with blood-derived viruses.Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency.Modeling HIV persistence, the latent reservoir, and viral blips.HIV latency.
P2860
Q25255905-493F2D6A-80ED-4CEB-A9F6-DC9C97796C54Q26827255-3089DFAE-890A-45A6-A966-A25FC16B4321Q27013114-45BEBD45-8072-4673-BFE7-0DAD6DA16DE4Q28482134-B89754A0-B51A-4300-99D4-42423163C9EDQ29619611-5EC9416C-A779-4D85-BE05-4AC63E035B4DQ30425443-289B9393-24FE-4A7C-953A-AE1924F5FF0AQ30558754-063C3987-B5C0-43C9-88CB-58EA843ECEBFQ33212237-824293E5-CBD8-4CD8-AD60-EDD677CA16CAQ33296883-E5E25DB5-4ADA-4C5C-8847-2975EB175668Q33302143-A06B87B6-EFBE-44E5-B25C-F52CD0F79F28Q33313038-29688B06-E7CF-4E1A-A565-574754FCACCCQ33510903-B751C574-4452-4479-B970-FB563098F084Q33724247-9C411AA6-1D4C-4D39-8304-65DD228880F7Q33737646-51891A0C-B72F-46B9-B806-5481E1339A89Q33908838-7C37989B-AC2D-44EF-A069-E237CB36AFB5Q34085094-FF845E71-BB98-4184-8E51-D7D483488E44Q34331710-788327BF-53A7-4E63-B66E-BF0027A3A54CQ34362894-8BF5E051-EE1C-4DC1-BA02-031E4D413352Q34639926-0D5FE464-7AD5-4743-BF93-7308246C6598Q34647680-0491C6C7-5847-4342-9B5B-792F2C0D1878Q34975321-71CDA29D-6BE6-4D36-B969-215975F7CDD0Q35044157-53505AF3-C866-4885-A6F6-2F7EA4FD1987Q35141776-D7E22A3F-FC09-48C8-AA0D-9DBE43502823Q35531964-573C123D-3D62-40F7-8BA8-ED4DEAC97A70Q35917148-539D6F69-31B6-4E7E-9F51-06ACAFB134F9Q35980789-F33EA224-961C-425B-B1A4-45627F79D367Q36238124-EC693115-276D-4CD1-853D-156F175A52D7Q36330062-4DCD6512-B204-4EC8-9E92-081ED930573EQ36390881-29C2F38E-E420-4CFD-9E26-CA6271DA7448Q36673315-F62C98AC-62A9-4159-9C62-96329C82B5A5Q36708954-FF98FA37-92E3-4EB9-AC6C-15B7F982A378Q36887625-2EE4AB59-0744-40B2-8430-EA864535EB06Q36943833-F728C47C-1DCE-4F56-8DD3-B17A7896ECB4Q36968375-59A4F914-F5E1-4F7C-A758-48DE1D4B0797Q37080573-361376F9-F1DF-4B4E-A57E-D3E4A4F93A03Q37133236-4414B9A2-B705-4280-98D9-5FDCA0A8742BQ37180837-172FDA02-3122-40FC-A4DC-7D33341722D6Q37348467-BCCA4707-166F-4D70-95FE-F41BAAEA3F31Q37365718-4D4993ED-A625-4D1F-B6D8-1953C3728682Q37974218-8D4CB300-50BA-4EC5-8ECF-5D2A4883FE90
P2860
Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Persistence of wild-type virus ...... nsive antiretroviral exposure.
@ast
Persistence of wild-type virus ...... nsive antiretroviral exposure.
@en
Persistence of wild-type virus ...... nsive antiretroviral exposure.
@nl
type
label
Persistence of wild-type virus ...... nsive antiretroviral exposure.
@ast
Persistence of wild-type virus ...... nsive antiretroviral exposure.
@en
Persistence of wild-type virus ...... nsive antiretroviral exposure.
@nl
prefLabel
Persistence of wild-type virus ...... nsive antiretroviral exposure.
@ast
Persistence of wild-type virus ...... nsive antiretroviral exposure.
@en
Persistence of wild-type virus ...... nsive antiretroviral exposure.
@nl
P2093
P2860
P50
P921
P1433
P1476
Persistence of wild-type virus ...... nsive antiretroviral exposure.
@en
P2093
Amanda Pendleton
Christian T Ruff
Deborah Persaud
Nancy Hutton
Patricia Kwon
Rebekah Zinn
Roxann Ashworth
P2860
P304
P356
10.1128/JVI.76.18.9481-9492.2002
P407
P577
2002-09-01T00:00:00Z